Search results
Showing 181 to 195 of 1092 results for infections
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote the appropriate use of antimicrobials?...
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
Bronchoscopic thermal vapour ablation for upper-lobe emphysema (HTG517)
Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults. This involves using steam to destroy the diseased part of the lung.
View recommendations for HTG517Show all sections
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Evidence-based recommendations on Prontosan for treating acute and chronic wounds.
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
- Quality statement 7: Recovery and reintegration
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making